Posttraumatic stress disorder in male military veterans with comorbid overweight and obesity: Psychotropic, antihypertensive, and metabolic medications

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 8, Issue 1, 2006, Pages 25-31

  Vieweg, W Victor R ^a,b,c   Julius, Demetrios A ^a,b   Fernandez, Antony ^a,b   Tassone, Daniel M ^a   Narla, Shireesha N ^a   Pandurangi, Anand K ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIHYPERTENSIVE AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; GABAPENTIN; IMIPRAMINE; METHYLPHENIDATE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PHENOBARBITAL; PHENYTEK; PHENYTOIN; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROATE SEMISODIUM; VENLAFAXINE; ZOLPIDEM; ZOLPIDEM TARTRATE;

ADULT; AGED; BODY MASS; COMORBIDITY; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MILITARY SERVICE; OBESITY; POSTTRAUMATIC STRESS DISORDER; PRIMARY MEDICAL CARE; REVIEW; SIDE EFFECT; VETERAN; WEIGHT GAIN;

EID: 33747023553     PISSN: 15235998     EISSN: None     Source Type: Journal    
DOI: 10.4088/pcc.v08n0104     Document Type: Review

References (42)

1. Das SR, Kinsinger LS, Yancy WS, et al. Obesity prevalence among veterans at Veterans Affairs medical facilities. Am J Prev Med 2005;28:291-294
2. Schnurr PP, Friedman MJ, Bernardy NC. Research on posttraumatic stress disorder: epidemiology, pathophysiology, and assessment. J Clin Psychol 2002;58(pt 5):877-883
3. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder. Am J Psychiatry 2004;161(suppl 11):1-31
4. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005;118(suppl 2):15S-22S
5. Vieweg WVR, Kuhnley LJ, Kuhnley EJ, et al. Body mass index (BMI) in newly admitted child and adolescent psychiatric inpatients. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:511-515
6. Kelly DL, Conley RR, Love RC, et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol 1998;8:151-159
7. Ghaemi SN, Katzow JJ. The use of quetiapine for treatment-resistant bipolar disorder: a case series. Ann Clin Psychiatry 1999;11:137-140
8. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696
9. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999;156:702-709
10. Melkerrson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000;61:742-749
11. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2000;57:841-849
12. Remschmidt H, Hennighausen K, Clement H-W, et al. Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 2000;9(suppl 1):I9-I19
13. Martin A, Landau J, Leebens P, et al. Risperidone-associated weight gain in children and adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol 2000;10:259-268
14. Haapasalo-Pesu K, Saarijarvi S. Olanzapine induces remarkable weight gain in adolescent patients. Eur Child Adolesc Psychiatry 2001;10:205-208
15. Sanger TM, Grundy SL, Gibson PJ, et al. Long-term olanzapine therapy in the treatment of bipolar I disorder: an open-label continuation phase study. J Clin Psychiatry 2001;62:273-281
16. Cohen S, Glazewski R, Khan S, et al. Weight gain with risperidone among patients with mental retardation: effect of caloric restriction. J Clin Psychiatry 2001;62:114-116
17. Theisen FM, Linden A, Geller F, et al. Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication. J Psychiatr Res 2001;35:339-345
18. Hellings JA, Zarcone JR, Crandall K, et al. Weight gain in a controlled study of risperidone in children, adolescents, and adults with mental retardation and autism. J Child Adolesc Psychopharmacol 2001;11:229-238
19. Aman MG, De Smedt G, Derivan A, et al. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002;159:1337-1346
20. Werneke U, Taylor D, Sanders TAB. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol 2002;17:145-160
21. Ratzoni G, Gothelf D, Brand-Gothelf A, et al. Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry 2002;41:337-343
22. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-321
23. Martin A, L'Ecuyer S. Triglycerides, cholesterol and weight changes among risperidone treated youths: a retrospective study. Eur Child Adolesc Psychiatry 2002;11:129-133
24. Pavuluri MN, Janicak PG, Carbray J. Topiramate plus risperidone for controlling weight gain and symptoms in preschool mania. J Child Adolesc Psychopharmacol 2002;12:271-273
25. Snyder R, Turgay A, Aman M, et al. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J Am Acad Child Adolesc Psychiatry 2002;41:1026-1036
26. Gothelf D, Falk B, Singer P, et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002;159:1055-1057
27. Masi G, Cosenza A, Mucci M, et al. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry 2003;64:1039-1047
28. Zalsman G, Carmon E, Martin A, et al. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. J Child Adolesc Psychopharmacol 2003;13:319-327
29. Mozes T, Greenberg Y, Spivak B, et al. Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study. J Child Adolesc Psychopharmacol 2003;13:311-317
30. Ross RG, Novins D, Farley GK, et al. A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol 2003;13:301-309
31. Moyers SB. Medications as adjunct therapy for weight loss: approved and off-label agents in use. J Am Diet Assoc 2005;105:948-959
32. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
33. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288:1723-1727
34. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-79
35. Sturm R. Increases in clinically severe obesity in the United States, 1986-2000. Arch Intern Med 2003;163:2146-2148
36. Freedman DS, Khan LK, Serdula MK, et al. Trends and correlates of class 3 obesity in the United States from 1990 through 2000. JAMA 2002;288:1758-1761
37. Flegal KM, Graubard BI, Williamson DF, et al. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005;293:1861-1867
38. Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. JAMA 2003;289:187-193
39. Dixon JB, Dixon ME, O'Brien PE. Depression in association with severe obesity: changes with weight loss. Arch Intern Med 2003;163:2058-2065
40. Arterburn DE, Maciejewski ML, Tsevat J. Impact of morbid obesity on medical expenditures in adults. Int J Obes Relat Metab Disord 2005;29:334-339
41. Arterburn DE, McDonell MB, Hedrick SC, et al. Association of body weight with condition-specific quality of life in male veterans. Am J Med 2004;117:738-746
42. David D, Woodward C, Esquenazi C, et al. Comparison of comorbid physical illnesses among veterans with PTSD and veterans with alcohol dependence. Psychiatr Serv 2004;55:82-85